-transparent.png){kind=logo}
Clinical and bacteriologic results are reported for 80 patients treated with 1.5--12 g of cefamandole daily for a variety of infections caused by Enterobacter and indole-positive Proteus, organisms that have been resistant to most available cephalosporins. Of 45 patients with infections due to Enterobacter, 41 (91%) had satisfactory clinical responses; 36 were bacteriologic successes, and six cases of complicated urinary tract infections relapsed. Of 37 patients with infections due to indole-positive Proteus, 28 (88%) were clinical successes and 30 (81%) were bacteriologic successes. Fourteen cases of complicated urinary tract infection relapsed. Of 104 patients in whom the drug was evaluated for safety, use of cefamandole was discontinued in five; nine adverse reactions were considered drug-related. A summary of published in vitro data shows that the majority of strains of these organisms were susceptible to cefamandole at concentrations achievable in the serum. Minimal inhibitory concentrations are variable, and there is a significant inoculum effect, the clinical significance of which has not been determined.
L R Levine, and
E McCain
July 1975,
Current therapeutic research, clinical and experimental,
L R Levine, and
E McCain
January 2017,
Clinical therapeutics,
L R Levine, and
E McCain
March 1972,
Applied microbiology,
L R Levine, and
E McCain
April 1952,
The American journal of the medical sciences,
L R Levine, and
E McCain
February 1949,
Hospital (Rio de Janeiro, Brazil),
L R Levine, and
E McCain
September 1996,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
L R Levine, and
E McCain
May 1973,
Fortschritte der Medizin,
L R Levine, and
E McCain
February 1983,
Zhurnal mikrobiologii, epidemiologii i immunobiologii,
L R Levine, and
E McCain
January 1982,
Chemotherapy,
L R Levine, and
E McCain
December 1988,
Klinische Wochenschrift,
